{
  "id": "adv_mhgap#management_9957062d",
  "content": "191. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy 198. Schneider-Thoma J, Chalkou K, Dörries C, Bighelli\nM, Komossa K et al. Maintenance treatment with I, Ceraso A, Huhn M et al. Comparative efficacy and\nantipsychotic drugs for schizophrenia. Cochrane tolerability of 32 oral and long-acting injectable\nDatabase Syst Rev. 2020;(8):CD008016. antipsychotics for the maintenance treatment\nof adults with schizophrenia: a systematic\n192. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis\nreview and network meta-analysis. Lancet.\nD, Helfer B et al. Sixty years of placebo-controlled\n2022;399(10327):824–36 (https://doi.org/10.1016/\nantipsychotic drug trials in acute schizophrenia:\nS0140-6736(21)01997-8).\nsystematic review, Bayesian meta-analysis, and\nmeta-regression of efficacy predictors. Am J 199. Krause M, Zhu Y, Huhn M, Schneider-Thoma J,\nPsychiatry. 2017;174(10):927–42 (https://doi. Bighelli I, Chaimani A et al. Efficacy, acceptability,\norg/10.1176/appi.ajp.2017.16121358). and tolerability of antipsychotics in children\nand adolescents with schizophrenia: a network\n193. Schneider-Thoma J, Efthimiou O, Huhn M, Krause\nmeta-analysis. Eur Neuropsychopharmacol.\nM, Reichelt L, Röder H et al. Second-generation\n2018;28(6):659–74 (https://doi.org/10.1016/j.\nantipsychotic drugs and short-term mortality:\neuroneuro.2018.03.008).\na systematic review and meta-analysis of\nplacebo-controlled randomised controlled trials. 200. DelBello MP, Kadakia A, Heller V, Singh R, Hagi K,\nLancet Psychiatry. 2018;5(8):653–63 (https://doi. Nosaka T et al. Systematic review and network",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "work",
      "management"
    ],
    "is_clinical": true,
    "is_advice": true
  },
  "index_text": "General — Management 191. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy 198. Schneider-Thoma J, Chalkou K, Dörries C, Bighelli\nM, Komossa K et al. Maintenance treatment with I, Ceraso A, Huhn M et al. Comparative efficacy and\nantipsychotic drugs for schizophrenia. Cochrane tolerability of 32 oral and long-acting injectable\nDatabase Syst Rev. 2020;(8):CD008016. antipsychotics for the maintenance treatment\nof adults with schizophrenia: a systematic\n192. Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis\nreview and network meta-analysis. Lancet.\nD, Helfer B et al. Sixty years of placebo-controlled\n2022;399(10327):824–36 (https://doi.org/10.1016/\nantipsychotic drug trials in acute schizophrenia:\nS0140-6736(21)01997-8).\nsystematic review, Bayesian meta-analysis, and\nmeta-regression of efficacy predictors. Am J 199. Krause M, Zhu Y, Huhn M, Schneider-Thoma J,\nPsychiatry. 2017;174(10):927–42 (https://doi. Bighelli I, Chaimani A et al. Efficacy, acceptability,\norg/10.1176/appi.ajp.2017.16121358). and tolerability of antipsychotics in children\nand adolescents with schizophrenia: a network\n193. Schneider-Thoma J, Efthimiou O, Huhn M, Krause\nmeta-analysis. Eur Neuropsychopharmacol.\nM, Reichelt L, Röder H et al. Second-generation\n2018;28(6):659–74 (https://doi.org/10.1016/j.\nantipsychotic drugs and short-term mortality:\neuroneuro.2018.03.008).\na systematic review and meta-analysis of\nplacebo-controlled randomised controlled trials. 200. DelBello MP, Kadakia A, Heller V, Singh R, Hagi K,\nLancet Psychiatry. 2018;5(8):653–63 (https://doi. Nosaka T et al. Systematic review and network 191. ceraso a, lin jj, schneider-thoma j, siafis s, tardy 198."
}